X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Glenmark Pharma with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs ADCOCK INGRAM (S. Africa) - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 GLENMARK PHARMA   ADCOCK INGRAM
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-18
ADCOCK INGRAM
Jun-14
GLENMARK PHARMA/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs930352-   
Low Rs517254-   
Sales per share (Unadj.) Rs322.6104.8-  
Earnings per share (Unadj.) Rs28.5-26.4-  
Cash flow per share (Unadj.) Rs39.2-21.9-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.30-  
Book value per share (Unadj.) Rs183.082.3-  
Shares outstanding (eoy) m282.17168.78-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.22.9 77.5%   
Avg P/E ratio x25.4-11.5 -221.2%  
P/CF ratio (eoy) x18.5-13.9 -133.3%  
Price / Book Value ratio x4.03.7 107.3%  
Dividend payout %7.00-   
Avg Mkt Cap Rs m204,20651,185 399.0%   
No. of employees `00013.74.3 319.5%   
Total wages/salary Rs m18,7183,212 582.7%   
Avg. sales/employee Rs Th6,636.84,120.8 161.1%   
Avg. wages/employee Rs Th1,364.7748.3 182.4%   
Avg. net profit/employee Rs Th586.1-1,038.3 -56.4%   
INCOME DATA
Net Sales Rs m91,03117,690 514.6%  
Other income Rs m914124 737.8%   
Total revenues Rs m91,94517,814 516.1%   
Gross profit Rs m16,154-3,066 -526.9%  
Depreciation Rs m3,019764 395.4%   
Interest Rs m2,856479 595.9%   
Profit before tax Rs m11,193-4,184 -267.5%   
Minority Interest Rs m0-12 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,155261 1,206.5%   
Profit after tax Rs m8,039-4,458 -180.3%  
Gross profit margin %17.7-17.3 -102.4%  
Effective tax rate %28.2-6.2 -451.0%   
Net profit margin %8.8-25.2 -35.0%  
BALANCE SHEET DATA
Current assets Rs m69,88712,957 539.4%   
Current liabilities Rs m32,8797,290 451.0%   
Net working cap to sales %40.732.0 126.9%  
Current ratio x2.11.8 119.6%  
Inventory Days Days81111 73.4%  
Debtors Days Days93124 75.4%  
Net fixed assets Rs m28,8927,552 382.5%   
Share capital Rs m28282 343.6%   
"Free" reserves Rs m51,3530-   
Net worth Rs m51,63513,885 371.9%   
Long term debt Rs m41,4184,879 848.8%   
Total assets Rs m125,95426,230 480.2%  
Interest coverage x4.9-7.7 -63.6%   
Debt to equity ratio x0.80.4 228.3%  
Sales to assets ratio x0.70.7 107.2%   
Return on assets %8.6-15.2 -57.0%  
Return on equity %15.6-32.1 -48.5%  
Return on capital %15.1-19.8 -76.2%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m26,5980-   
CASH FLOW
From Operations Rs m16,4811,510 1,091.4%  
From Investments Rs m-10,133-464 2,185.6%  
From Financial Activity Rs m-4,6854,428 -105.8%  
Net Cashflow Rs m1,7705,475 32.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 4.86 Rs / ZAR

Compare GLENMARK PHARMA With: ACTAVIS (US)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare GLENMARK PHARMA With: JUBILANT LIFE SCIENCES  ELDER PHARMA  AUROBINDO PHARMA  SANOFI INDIA  ORCHID PHARMA LTD  



Today's Market

Indian Share Markets Open Flat; Rupee Hits 70-Mark Again(09:30 am)

Asian stock markets are lower today as Chinese and Hong Kong shares fall. The Shanghai Composite is off 0.5% while the Hang Seng is flat.

Related Views On News

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, GLENMARK PHARMA has posted a net profit of Rs 4 bn (up 93.3% YoY). Sales on the other hand came in at Rs 26 bn (up 14.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

More Views on News

Most Popular

This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)

Apr 12, 2019

This critical business strategy has enabled companies to scale their operations faster.

Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)

Apr 12, 2019

Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.

My Master Series on How to Trade Election 2019(Profit Hunter)

Apr 16, 2019

For 30 years he has watched how elections impact the markets, and practiced how to profit from it. Now he is here...telling you everything. Read on...

Election Series: Follow the World's Biggest Traders To See Where the Money Flows(The 5 Minute Wrapup)

Apr 17, 2019

20% of all the traders bring in 80% of the money. Watch these 20% and you get a working idea of which way the wind is blowing.

A Letter to You from India's No. 1 Trader(The 5 Minute Wrapup)

Apr 15, 2019

It's our great pleasure to introduce Vijay Bhambwani to our readers - we consider Vijay to be India's best trader. Read on to find out why...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Apr 25, 2019 11:49 AM

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS